CLINICAL ROLE -
The Unusual Discovery of Commonly Prescribed Medications: Part 4
This article will describe the unusual discovery of 5 commonly prescribed medications, many of which were through serendipitous events.
Read More
First Short-Course Oral Therapy for Relapsing Forms of MS Granted FDA Approval
Cladribine (Mavenclad, EMD Serono) is the first oral multiple sclerosis drug to demonstrate 2 years of proven efficacy with a maximum of 20 days of treatment.
First Short-Course Oral Therapy Approved for Relapsing Forms of MS
New Indication Approval Sought for Icosapent Ethyl
Study data suggest the drug helps reduce the risk of major adverse cardiovascular event in certain patients.
The iStopMM Trial & Importance of Early Screening
Watch
The Future of Oral Oncolytics
The Role of Payers in the Dispensing Process
Pearl 4: Using a Collaborative Care Plan for the Treatment of MM
Difficulties of the Multiple Myeloma Treatment Continuum
The Role of Specialty Pharmacies in the Dispensing Process
The Dispensing Capabilities of Pharmacies
Pearl 3: Avoiding Delays During Prior Authorization Process
The Risk Evaluation and Mitigation Strategies (REMS) Program
Pearl 1: Oral Parity Laws and Their Impact on Cost
Pearl 1: The Use of Co-Pay Cards to Solve an Economic Burden
Oral Oncolytic Treatment Options for Multiple Myeloma
Medicare Coverage of Oral Oncolytics
The Economic Burden of Multiple Myeloma Treatment
First-in-Human Clinical Trial Studying HIV Vaccine Candidate
The goals are to assess the candidate’s safety and to determine if the vaccination induces the human immune system to produce proteins called neutralizing antibodies.
April's Rosacea Awareness Initiative Emphasizes Benefits of Achieving Clear Skin
The National Rosacea Society (NRS) has designated April as Rosacea Awareness month to improve education of rosacea.
Immunotherapy for Pre-Cancerous Lesions May Reduce Skin Cancer Risk Over Time
The combination therapy reduced the risk of squamous cell carcinoma development on the face and scalp by approximately 75% in the study.
First Oral Drug for Secondary Progressive MS Tops SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
Trending News Today: Pharmacists, Dermatologists Counsel Differently on Topical Steroid Use
Top news of the day from across the health care industry.
First Treatment for Non-Radiographic Axial Spondyloarthritis Granted FDA Approval
With this approval, certolizumab pegol becomes the first FDA-approved therapy for this type of axSpA, filling an unmet clinical need for treatment options, according to the release.
New CDC Guidance Recommends Artesunate as First-Line Treatment for Severe Malaria
The action follows discontinuation of quinidine, the only FDA-approved intravenous antimalarial drug in the United States.
FDA Approves First Treatment for Non-Radiographic Axial Spondyloarthritis
Certolizumab pegol (Cimzia) is the first FDA-approved therapy for this type of axial spondyloarthritis, filling an unmet clinical need for treatment options.
Pharmacy's Past: Chemist Discovers Aspirin and Heroin
Aspirin and heroin were discovered within weeks of each other in 1897 by Felix Hoffmann.
ASHP Midyear Clinical Meeting Ranks Among Top US Trade Shows
ASHP’s Midyear Clinical Meeting rose 5 spots, from No. 157 to No. 152 out of 250 trade shows with the Consumer Electronics Shows (CES) topping the list.
Study: Older, Urban Men Most Likely to Achieve Medication Persistence with PrEP
Overall, more than half of commercially insured individuals who initiated pre-exposure prophylaxis persisted with it for the 12-month duration of the cohort study.
Most New HIV Transmissions in US Fueled by Undiagnosed, Untreated Infection
An updated transmission model indicates that most new HIV infections occur due to a lack of diagnosis and treatment.
